← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	1,680	+135	+9%	$116B
2	2 Danaher DHR $158B	1,517	+90	+6%	$85.5B
3	3 Novartis NVS $279B	1,173	+82	+8%	$24.4B
4	4 Illumina ILMN $41B	890	+68	+8%	$45B
5	5 Agilent Technologies A $49.1B	752	+52	+7%	$22.8B
6	6 Regeneron Pharmaceuticals REGN $80.1B	703	+70	+11%	$27.7B
7	7 Revvity RVTY $17B	430	+12	+3%	$10.5B
8	8 Charles River Laboratories CRL $14.4B	413	+17	+4%	$7.23B
9	9 Ionis Pharmaceuticals IONS $7.1B	391	+21	+6%	$7.3B
10	10 Sarepta Therapeutics SRPT $1.78B	390	+49	+14%	$9.51B
11	11 Alnylam Pharmaceuticals ALNY $30B	316	+35	+12%	$12.3B
12	12 Qiagen QGEN $9.41B	297	+53	+22%	$5.13B
13	13 Azenta AZTA $1.63B	293	+46	+19%	$2.99B
14	14 Arrowhead Research ARWR $8.25B	291	+70	+32%	$4.13B
15	15 DELISTED CATALENT, INC. CTLT	288	-10	-3%	$8.43B
16	16 Bruker BRKR $8.47B	275	+26	+10%	$5.44B
17	17 DELISTED bluebird bio BLUE	274	+33	+14%	$5.27B
18	18 Guardant Health GH $21.9B	268	+26	+11%	$6.03B
19	19 CRISPR Therapeutics CRSP $4.86B	253	+71	+39%	$1.92B
20	20 Editas Medicine EDIT $349M	229	+42	+22%	$1.36B
21	21 Myriad Genetics MYGN $397M	227	+6	+3%	$2.15B
22	22 PTC Therapeutics PTCT $4.98B	206	+22	+12%	$2.94B
23	23 DELISTED SANGAMO THERAPEUTICS INC SGMO	193	+9	+5%	$657M
24	NVTA 24 DELISTED Invitae Corporation NVTA	190	+7	+4%	$1.6B
25	25 Regenxbio RGNX $454M	187	+19	+11%	$1.23B